CogState Stock

CogState Equity Growth

Delisted·Jun 15, 2026

The Year-over-Year Equity Growth of CogState (CGS.AX) as of Aug 7, 2026 is 17.05 %. In the previous year, Year-over-Year Equity Growth was 8.58 % — a change of 98.71% (higher).

Equity Growth

17.05 %

YoY

98.71%

Last updated:

Year-over-Year Equity Growth of CogState is 2026 17.05 % . Year-over-Year Equity Growth of CogState was 2025 8.58 % . It decreases by 98.71% higher compared to the previous year.
Access this data via the Eulerpool API

CogState Stock analysis

What does CogState do? CogState Ltd is an Australian company specializing in the development of innovative cognitive tests. The company was founded in 1999 and is based in Melbourne, Australia. It conducts computer-based cognitive tests to gather information about the cognitive functioning of patients and athletes. The CogState tests are specifically designed to measure cognitive abilities in areas such as perception, reaction time, memory, and attention. The business model of CogState is based on the development, marketing, and sale of cognitive test products. The company generates a significant portion of its revenue through licensing its tests to pharmaceutical and biotech companies that want to test their medications or therapies more effectively. CogState also has a strong presence in the sports industry, offering its tests to sports teams and individual athletes. CogState was founded in 1999 by Paul Maruff, a neuropsychologist, who was searching for better and more effective ways to conduct cognitive tests. Initially, the tests developed by CogState were exclusively for medical research, but it was quickly discovered that they could be useful in other areas as well. In 2004, Richard Kimber joined the company as CEO and Chairman, bringing his experience from the biotechnology industry. CogState offers a variety of cognitive tests for various applications, including clinical trials, sports performance analysis, and brain injury treatment. The tests are licensed by different companies and organizations that use them to test the effects of medications and therapies on cognitive functions or to assess performance and injuries in sports. One example of a CogState product is the AX Continuous Tracker Test. This test was developed for clinical use and allows for continuous and accurate measurement of cognitive functions in patients with psychiatric and neurological disorders. Another application is the SPARQ test for athletes, which allows for the measurement and improvement of athletes' cognitive abilities. In summary, CogState Ltd is a leading company in the field of cognitive tests. The company specializes in developing innovative cognitive tests for the specific requirements of pharmaceutical and biotech companies, as well as sports organizations. The tests are used worldwide by various organizations and have a significant impact on the treatment of psychiatric and neurological disorders, as well as performance and injury analysis in sports. CogState is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CogState stock

Year-over-Year Equity Growth of CogState is 17.05 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth CogState since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's CogState historically and in real time.

Access this data via the Eulerpool API

Growth — CogState

All Key Metrics — CogState